Will increasingly bitter patent disputes stifle scientific medical research? A recent Commentary article about a sandwich immunoassay has provoked this exchange.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Ekins, R. Nature 340, 256–258 (1989).
Hybritech Incorporated v. Abbott Laboratories 4 U.S.P.Q. 2d at 1008–10.
Hybritech Incorporated v. Monoclonal Antibodies, Inc. 623 F. Supp. 1344, 227 U.S.P.Q. 215 (N. D. Cal. 1985).
Hybritech Incorporated v. Monoclonal Antibodies, Inc., 802 F. 2d 1367, 231 U.S.P.Q. 81 81 (Fed. Cir. 1986), cert, denied, 107 S. Ct. 1606 (1987).
Hybritech Incorporated v. Abbott Laboratories, 4 U.S.P.Q. 2d 1001 (C. D. Cal. 1987).
Hybritech Incorporated v. Abbott Laboratories, 849 F. 2d 1446, 7 U.S.P.Q. 2d 1191 (Fed. Cir. 1988).
Article 1, Section 8, Clause 8.
The Federalists No. 43, at 267.
Cong. Rec. at 901 (20 January 1962).
Drews, G. The Patent Right in the National Economy of the United States at 140 (1952).
Coe. TNEC Hearings Part III, at 856 (1939).
UK patent application GB2150288B. Inhibition Assays Using Monoclonal Antibodies.
UK patent application GB2086041A. Immunoassay Utilising Monoclonal Antibodies.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Greene, H., Duft, B. & Ekins, R. Disputes over monoclonal antibodies. Nature 347, 117–118 (1990). https://doi.org/10.1038/347117a0
Issue date:
DOI: https://doi.org/10.1038/347117a0
